GTN

The AI engine Fit Assessment

Beta

GTN effectively utilizes machine learning and pattern discovery to innovate drug discovery, expanding therapeutics and optimizing the process.

Blurb

GTN innovates a quantum machine learning technology to transform drug discovery.

HQ Location

London (United Kingdom)

Founded

2017

Employees

11 - 50

Total funding raised

$2.84M

Last Funding Event

Seed, November 1, 2018

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Discovery Optimization

Bringing a single new drug to the market costs $2.9bn, often delivering an intervention that barely differs from those already in the market. Projections into the future are not promising, with an expected 50% drop in R&D output every nine years. At GTN they are searching the astronomically large space of drug-like molecules with their unique patented technology, Generative Tensorial Networks. Their software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, halving development costs and discovering molecules entirely hidden from view.